Recent News

• 09.12.2025 - The CAM-E ALG-001075 potently reduces HBV cccDNA in preclinical experiments
• 09.05.2025 - H.C. Wainwright 27th Annual Global Investment Conference
• 09.03.2025 - Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting
• 09.02.2025 - Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
• 08.20.2025 - Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs
• 08.15.2025 - Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 08.13.2025 - Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection
• 08.06.2025 - Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results
• 07.30.2025 - Aligos Therapeutics to Announce 2nd Quarter 2025 Financial Results on August 6, 2025
• 07.11.2025 - Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.13.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.12.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.06.2025 - 8-K Current report
• 08.06.2025 - EX-99.1 EX-99.1
• 08.06.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 08.06.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.18.2025 - 4 Statement of changes in beneficial ownership of securities